Video | July 29, 2020

Challenges And Solutions Around Diversity And Inclusion In Clinical Trials During A Pandemic

Source: Life Science Leader

Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmas (view full video here). In this component, Rachel King, CEO of GlycoMimetics, (NASDAQ: GLYC), Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics (NASDAQ: OVID), Gil Van Bokkelen, Ph.D., chairman and CEO of Athersys (NASDAQ: ATHX), and Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), discuss some of the challenges and solutions for making clinical trials diverse and inclusive during the pandemic.